Modality
Radioligand
MOA
CDK2i
Target
Cl18.2
Pathway
Tau
Endometrial CaObesityAlzheimer's
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
~Sep 2021
→ ~Dec 2022
Phase 2
Mar 2023
→ Jul 2031
Phase 2Current
NCT08905994
2,251 pts·Alzheimer's
2023-03→2031-07·Recruiting
2,251 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-135.3y awayPh2 Data· Alzheimer's
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Recruit…
Catalysts
Ph2 Data
2031-07-13 · 5.3y away
Alzheimer's
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08905994 | Phase 2 | Alzheimer's | Recruiting | 2251 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A |